Natera, Inc. — Investor Relations & Filings

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing. The company develops and commercializes non-invasive tests focused on three primary areas: women's health, oncology, and organ health. In women's health, its products include the Panorama non-invasive prenatal test (NIPT) and the Horizon carrier screening test to assess genetic risks. The oncology portfolio features Signatera, a personalized molecular residual disease (MRD) test used to monitor cancer recurrence and treatment response. For organ health, its tests are designed to detect early signs of transplant rejection. Natera's technology aims to provide actionable information for personalized medical care, supported by extensive clinical validation through numerous peer-reviewed studies.